IAS 2012 feedback: www.i-Base.info UK Consortium: September 2012 IAS 2012 Feedback: New findings, better drugs and the goal of a cure Simon Collins HIV.

Slides:

Advertisements

Similar presentations

HIV/AIDS The Epidemic in ANE and E&E So what do we do now? Paul De Lay Senior Advisor on HIV/AIDS Office of HIV/AIDS.

Advertisements

Scaling up HIV services for women and children achievements and challenges e-lluminate session e-lluminate session Yves Souteyrand 2 March 2010.

No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,

HIV treatment as prevention Stephen Kegg. 2 Learning Outcomes Overview of HIV management HIV transmission risks Current prevention strategies Which new.

The U.S. President’s Emergency Plan for AIDS Relief The Evolving HIV Prevention Strategy for IDUs in PEPFAR Amb. Eric Goosby US Global AIDS Coordinator.

The PEPFAR Blueprint for an AIDS Free Generation Implications for Uganda’s response to HIV Alice Kayongo-Mutebi, Community Health Alliance Uganda 14 February.

Towards an AIDS-Free Generation Women & Girls and HIV in PEPFAR

Early Infant Diagnosis: Challenges and Solutions A special session IAS, Vienna 2010.

Fabio Mesquita, MD, PhD Director of the Brazilian Ministry of Health’s HIV/AIDS and Viral Hepatitis Department July 20th, 2014 Evidence.

Office of Global Health and HIV (OGHH) Office of Overseas Programming & Training Support (OPATS) HIV Prevention Training Package Session 1: Introduction.

Scaling up Prevention of Mother to Child Transmission of HIV (PMTCT): What Will it Take to Eliminate MTCT? Jessica Rodrigues Presentation for UNICEF Written.

Marian Kerbleski, RN UCSF AIDS Division San Francisco General Hospital.

Strategies for Targeting and Eradicating the HIV Reservoir

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

Dr. Yogan Pillay Deputy Director General National Department of Health, South Africa Monday 1 July 2013 OPERATIONAL AND PROGRAMMATIC CONSIDERATIONS IN.

THE PREVENTION OF MOTHER TO CHILD TRANSMISSION of HIV (PMTCT)

Kevin Fenton, MD, PhD, FFPH Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Centers for Disease Control and Prevention.

"HIV Cure" 101 Workshop Current Community Questions and Concerns about “HIV Cure” Bill Whittaker National Association of People with HIV Australia.

2 About HIV: Teaching Tool. About HIV: A teaching tool © 2nd edition 2006 This tool was developed by the François-Xavier Bagnoud Center at the University.

Bloodborne Pathogens HIV, AIDS, and Hepatitis Unit 1.

A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.

What does PrEP mean for people living with HIV? Edwin J Bernard Co-ordinator, HIV Justice Network Consultant, GNP+

By David Velasquez Mr. Ippolito Biology Per. 8-9.

PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,

START study: UK-CAB July2015 Community feedback: START study Simon Collins HIV i-Base

HIV/AIDS: A Global and Regional Perspective AIDS in Post 2015 Development Agenda.

AIDS supplement. History of HIV Originated in Africa in the late 1950’s Originally found in nonhuman primates and may have mutated First documented in.

Office of Overseas Programming & Training Support (OPATS) Overview of Care, Support, and Treatment HIV Care, Support, and Treatment.

The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.

Models of Care for Paediatric HIV Miriam Chipimo MD MPH Reproductive Health & HIV&AIDS Manager, UNICEF, Malawi.

HIV & MNCH: Can we do one without the other? Key Issues & Emerging Evidence Presentation for the XVIII International AIDS Conference-AIDS 2010 Rights Here,

2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.

African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.

Resource Needs Model Rachel Sanders October 28 th, 2010.

GLOBAL UNITED CHILDREN’S FOUNDATION, Inc Presents “Using Education to Contain the Spread of HIV/AIDS in Africa and Expand Treatment in Rural Communities.

Update on HIV Therapy Elly T Katabira, FRCP Department of Medicine Makerere University Medical School Scaling up Treatment Programs: Issues, Challenges.

10 facts about AIDS Source: World Health Organization

The National HIV Counselling and Testing Campaign and Treatment Expansion in South Africa: A return on investments in combination prevention XIX International.

Martin Fisher Foundation: 14 September Remembering Martin Fisher Simon Collins, HIV i-Base Who should get tested? How and why should.

Prevention of HIV infection: How effectively are countries responding to changing epidemics in the Asia Pacific Region? 1.

Getting to Zero: Will San Francisco be the first city to succeed? Diane Havlir, MD, Professor of Medicine, UCSF, Chief HIV San Francisco General Hospital.

IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.

WORLD AIDS DAY Zero new HIV infections Zero discrimination Zero AIDS-related deaths.

MDG 6: Combat HIV/AIDS and other diseases. Where are we…  Regionally, “on track” for MDG-6 (only a few countries are progressing slowly or show no progress)

Pagare Maya & Yewale Sakhu. 1. We aimed at desiging on all purpose 9 th and 10 th std. students give the information of aids. Create the scientific attitude.

Fast-Tracking Treatment to End AIDS ICASA Ambassador Deborah Birx, MD U.S. Global AIDS Coordinator November 30, 2015.

Malaria a story of ELIMINATION A partnership of:.

The strategic use of ARVs Global evidence and experience to date Professor Charles Gilks UNAIDS India National Consultation on the Strategic Use of ARVs.

STATE OF THE EPIDEMIC AND THE RESPONSE PROMISES, PROGRESS AND PROBLEMS DR. ALEX COUTINHO MD MPH Executive Director Infectious Diseases Institute.

PMTCT 365 Days of Action to end the hidden violence against women and children Protecting Women early.

Commentary Thailand national guidelines for implementing HIV prevention among men who have sex with men and transgender populations As of March 2013 Frits.

Thematic Priorities for ATF Applications Presentation by Secretariat of Council for the AIDS Trust Fund in Briefing Session on 27 July

Contents Global impact 2.Service cascade 3. Policies and WHO support.

Financing HIV, Hepatitis and STI Strategies:

State of HIV Cure Research

3rd International HIV/Viral Hepatitis Co-Infection Meeting HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access Sunday, 17 July.

TREATMENT OF HIV.

27 years of responding to AIDS

Zimbabwe’s shift towards treat all: national country context

27 years of responding to AIDS

MOTHER TO CHILD TRANSMISSION of HIV

Richard hayes London school of hygiene & Tropical Medicine

AIDS supplement.

The Last Mile to EMTCT: Are we there yet?

New regimen for $75 a year New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs) HIV positive.

27 years of responding to AIDS

Where do we go from here? Gottfried Hirnschall Director HIV dept, WHO

Contents Global impact 2.Service cascade 3. Policies and WHO support.

Start Free, Stay Free, AIDS Free

HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE

Presentation transcript:

IAS 2012 feedback: UK Consortium: September 2012 IAS 2012 Feedback: New findings, better drugs and the goal of a cure Simon Collins HIV i-Base

IAS 2012 feedback: UK Consortium: September 2012 IAS take home Cure research: co-ordinated priority Move to earlier treatment is global (at CD4 500>350>200) - based on better drugs. Treatment is still the most effective proven intervention to reduce sexual transmission 8 million people on treatment in low and middle income countries

IAS 2012 feedback: UK Consortium: September 2012 IAS conferences Changing priorities over time reflect community-driven changes to medicine: IAS 1990, San Francisco: ACT-UP launch community research agenda with US National Guard backstage IAS 1998, Geneva: “delegates haemhorraged from session halls when presentations switched to the developing world” Richard Horton IAS 2000 Durban Barcelona: UNAIDS, Global Fund, PEPFAR, WHO 3x5 campaign

IAS 2012 feedback: UK Consortium: September 2012 IAS conferences Broader expansion for research related to treatment access, prevention, global health funding, human rights (IDU in Bangkok in 2004), MSM, women’s health, sex workers, children etc Total no. of studies Track A: Basic science Track B: Clinical science posters pub only 400 oral poster +100 pub only 400 oral 2575

IAS 2012 feedback: UK Consortium: September 2012 Cure research IAS focus: 3rd year for pre-conference workshop US and international funding. Roadmap for a cure: 7 key research areas each with numerous problems. What to measure, how, definitions, ethics and safety. (i-base.info/htb/19827) Early stages: 10 years away? (vaccine comparison?, “vaccine will come first”.

IAS 2012 feedback: UK Consortium: September 2012 Cure research: key parts of the puzzle Why does HIV persist: immune and viral factors Where does HIV persist: tissue and cell reservoirs Immune activation and dysfunction on ART Natural models of HIV/SIV control How to measure persistent infection How to reverse latency: treatments Immune approaches, gene therapy, vaccine

IAS 2012 feedback: UK Consortium: September 2012 Eradication vs functional cure Viral latency: long-lived sleeping CD4 cells - Why ARVs are not a cure and are lifelong. Strategies to wake cells (vorinostat). Ongoing replication?: Body tissues/cells where ARVs may not reach? importance? Gut, brain etc? CD4 recovery: incomplete with ARVs, immune activation, inflammation Immune-based treatment: gene therapy (ZFN CD4 changes), vaccines Cure research: key parts of the puzzle

IAS 2012 feedback: UK Consortium: September 2012 On vs off treatment SMART satellite workshop Importance of large randomised studies Changed expert opinion on untreated HIV Doctors, community and researchers Increased risk of major organ disease (heart, liver, kidney) and some cancers in people who interrupted treatment Caused by immune inflammation when not on treatment Link to some biomarkers (d-dimer, IL-6)

IAS 2012 feedback: UK Consortium: September 2012 Randomised studies and earlier treatment IAS-USA guidelines (July 2012) – recommendation for treatment irrespective of CD4 count START study: international randomised study of immediate treatment (CD4 >500) vs waiting until 350 (current UK and WHO guidelines)

IAS 2012 feedback: UK Consortium: September 2012 New drugs, generics and UK access i-Base/TAG pipeline report: HIV, hepatitis and TB drugs, tests and strategies: single-tablet fixed-dose combinations, paediatrics etc New drug pipeline includes numerous new single-pill formulations. Potential of integrase inhibitors Paediatric formulations

IAS 2012 feedback: UK Consortium: September 2012 New drugs and access in the UK Elvitegravir: once-daily integrase Dolutegravir: once-daily integrase (50 mg) Cobicistat: new “booster” BMS : d4T-like nuke Generic efavirenz/3TC and future NHS access to new drugs. $900,000 US savings (Walensky talk)

IAS 2012 feedback: UK Consortium: September 2012 Treatment as Prevention HTPN 052 widely quoted as “up to 96% reduction in transmission” Likely to significantly UNDER estimate protection: single case in study likely in first weeks of treatment Current impact from 8,000,000 Next few years will have fewer new infections in relation to people starting treatment – but only if funded.

IAS 2012 feedback: UK Consortium: September million people on treatment WHO 3x5 campaign: 3 million people on treatment by 2005 Started when only 300,000 people were on treatment Politically this was “too few” but other thought it unreaslistic for scale up Goal was missed in 2005 but 8 million people now on ARVs (2 million in S. Africa).

IAS 2012 feedback: UK Consortium: September million people on treatment “If we do not scale up treatment as prevention, if we do not reach 15 million people on treatment by 2015, if we do not eliminate new infections in children, if we do not close the ($7b) funding gap… history will never forgive us. The end of AIDS is not free, it is priceless.” Michel Sidibe (UNAIDS)

IAS 2012 feedback: UK Consortium: September 2012 Thank you